Mirdametinib

SUSPENDED · PHASE1, PHASE2 · Multiple Myeloma, Relapsed and/or Refractory Multiple Myeloma (RRMM)

Administrative hold pending non-safety related changes to the study design.

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.